Repare Therapeutics Inc Ordinary Shares RPTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RPTX is a good fit for your portfolio.
News
-
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
-
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
-
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
-
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors
-
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX
Trading Information
- Previous Close Price
- $3.28
- Day Range
- $3.57–3.94
- 52-Week Range
- $2.99–13.78
- Bid/Ask
- $3.68 / $3.72
- Market Cap
- $158.75 Mil
- Volume/Avg
- 3.5 Mil / 126,385
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company’s focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 179
- Website
- https://www.reparerx.com
Comparables
Valuation
|
Metric
|
RPTX
|
TYRA
|
ITOS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.65 | 3.78 | 0.77 |
Price/Sales | 2.70 | — | 34.95 |
Price/Cash Flow | — | — | — |
Price/Earnings
RPTX
TYRA
ITOS
Financial Strength
|
Metric
|
RPTX
|
TYRA
|
ITOS
|
|---|---|---|---|
Quick Ratio | 6.11 | 13.27 | 13.46 |
Current Ratio | 6.24 | 13.80 | 13.76 |
Interest Coverage | — | — | — |
Quick Ratio
RPTX
TYRA
ITOS
Profitability
|
Metric
|
RPTX
|
TYRA
|
ITOS
|
|---|---|---|---|
Return on Assets (Normalized) | −23.00% | −22.50% | −12.92% |
Return on Equity (Normalized) | −29.04% | −23.73% | −14.67% |
Return on Invested Capital (Normalized) | −33.39% | −27.79% | −18.54% |
Return on Assets
RPTX
TYRA
ITOS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pdbdrqmp | Ybrb | $567.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nbvsrbgl | Rtxfmy | $106.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kxlmwcvb | Jyysfk | $105.9 Bil | |
MRNA
| Moderna Inc | Jfltrtyy | Qsk | $46.4 Bil | |
ARGX
| argenx SE ADR | Lymzjbrkz | Ppdqs | $23.5 Bil | |
BNTX
| BioNTech SE ADR | Pdddjgf | Wdb | $21.9 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xszwpgr | Rgpkfs | $19.5 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Grdlvjdv | Gqbxtn | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jzrdzmdvgd | Qzlwcr | $12.8 Bil | |
INCY
| Incyte Corp | Thngmnkhc | Zldxp | $12.2 Bil |